Summit Therapeutics (SMMT) Stock Overview
A biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
SMMT Community Fair Values
Create NarrativeSee what 31 others think this stock is worth. Follow their fair value or set your own to get alerts.
Summit Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$18.74 |
| 52 Week High | US$36.91 |
| 52 Week Low | US$15.55 |
| Beta | -1.14 |
| 1 Month Change | -0.79% |
| 3 Month Change | -33.10% |
| 1 Year Change | -8.98% |
| 3 Year Change | 1,558.41% |
| 5 Year Change | 462.76% |
| Change since IPO | 82.12% |
Recent News & Updates
Recent updates
Summit's Bold BLA Without Stat-Sig OS: Why I Step Back To Hold
Oct 20Summit Therapeutics: New Ivonescimab Data Raise Concerns
Apr 26Summit Therapeutics: Not Pharmacyclics, Not Yet
Apr 12Summit Therapeutics: Major Upcoming Ivonescimab Data Catalyst May Not Be All It Seems (Rating Downgrade)
Mar 28Summit Therapeutics: Mid-2025 NSCLC Data Could Further Entrench Ivonescimab Program
Feb 24Health Check: How Prudently Does Summit Therapeutics (NASDAQ:SMMT) Use Debt?
Feb 22
Summit Therapeutics: Data Signals A Potential Paradigm Shift In NSCLC (Rating Upgrade)
Jan 18The Play On Summit Therapeutics
Jan 05Summit Therapeutics Stock Set To Soar By Mid-2025 On HARMONi Phase 3 Trial
Dec 02Summit Therapeutics (NASDAQ:SMMT) Has Debt But No Earnings; Should You Worry?
Nov 08Summit Therapeutics: Cancer Drug With Great Potential On 'Fast Track' To US Market
Oct 04Summit Therapeutics Bests Merck's Top Selling Drug In Phase III Trial
Sep 19Summit Therapeutics: World Lung Data Not Enough For Ivonescimab To Unseat Keytruda (Yet)
Sep 09Summit Therapeutics May Have Further Upside From Here
Aug 03Summit Therapeutics Stock: Plunging Despite A Win?
May 31Summit Therapeutics' Ivonescimab: Strong Buy Its Dual-Action Approach To Cancer
May 06Summit Therapeutics: A Strategic Analysis Of Ivonescimab's Progress
Jan 30Summit Therapeutics slips on plans to terminate study for lead candidate
Oct 04Summit Therapeutics: Developing Antibiotics Is A Noble Cause But The Company Is Wise To Expand Its Portfolio
Aug 17Summit Therapeutics GAAP EPS of -$0.17, revenue of $0.23M
Aug 11Summit to explore additional trial for its bacteria-induced colon infection drug
Jul 14Shareholder Returns
| SMMT | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -13.8% | 3.0% | 1.1% |
| 1Y | -9.0% | 2.7% | 16.7% |
Return vs Industry: SMMT underperformed the US Biotechs industry which returned 3.1% over the past year.
Return vs Market: SMMT underperformed the US Market which returned 16.3% over the past year.
Price Volatility
| SMMT volatility | |
|---|---|
| SMMT Average Weekly Movement | 11.1% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 17.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: SMMT's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: SMMT's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 159 | Bob Duggan | www.smmttx.com |
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis, as well as in Phase III clinical trials for the treatment of non-small lung cancer. The company was founded in 2003 and is headquartered in Miami, Florida.
Summit Therapeutics Inc. Fundamentals Summary
| SMMT fundamental statistics | |
|---|---|
| Market cap | US$14.91b |
| Earnings (TTM) | -US$921.62m |
| Revenue (TTM) | n/a |
Is SMMT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SMMT income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$921.62m |
| Earnings | -US$921.62m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.24 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did SMMT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/21 11:07 |
| End of Day Share Price | 2025/10/21 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Summit Therapeutics Inc. is covered by 24 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Etzer Darout | Barclays |
| Timothy Chiang | BTIG |
| Arlinda Lee | Canaccord Genuity |